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Abstract 
Molecular pathological epidemiology (MPE) is a transdisciplinary and relatively new 
scientific discipline that integrates theory, methods and resources from epidemiology, 
pathology, biostatistics, bioinformatics and computational biology. The underlying 
objective of MPE research is to better understand the etiology and progression of 
complex and heterogeneous human diseases with the goal of informing prevention and 
treatment efforts in population health and clinical medicine. Although MPE research has 
been commonly applied to investigating breast, lung, and colorectal cancers, its 
methodology can be used to study most diseases. Recent successes in MPE studies 
include: 1) the development of new statistical methods to address etiologic 
heterogeneity; 2) the enhancement of causal inference; 3) the identification of 
previously unknown exposure-subtype disease associations; and 4) better 
understanding of the role of lifestyle/behavioral factors on modifying prognosis 
according to disease subtype. Central challenges to MPE include the relative lack of 
transdisciplinary experts, educational programs, and forums to discuss issues related to 
the advancement of the field. To address these challenges, highlight recent successes 
in the field, and identify new opportunities, a series of MPE meetings have been held at 
the Dana-Farber Cancer Institute in Boston, MA. Herein, we share the proceedings of 
the Third International MPE Meeting, held in May 2016 and attended by 150 scientists 
from 17 countries. Special topics included integration of MPE with immunology and 
health disparity research. This meeting series will continue to provide an impetus to 
foster further transdisciplinary integration of divergent scientific fields. 
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Introduction 
Molecular pathological epidemiology (MPE) is an integrative scientific discipline that 
examines the interplay of risk and prognostic factors with pathology tissue-based 
biomarkers of health and disease in human populations. Although molecular pathology 
had been integrated into epidemiologic research for decades, it was only in 2010 when 
the integrative field that unified molecular pathology and epidemiology was first 
described in the literature (1). Since then, the field of MPE has expanded considerably 
to advance population health sciences (2-4).  
As a sub-discipline of epidemiology, MPE studies are usually drawn from larger 
prospective cohort (e.g., Nurses’ Health Study, Cancer Prevention Study-II) or case-
control (e.g., Breast and Colon Cancer Family Registries) studies that are supported to 
collect and to use pathology specimens. In an MPE paradigm, a potential etiologic 
factor is assessed with risk of an outcome across strata of molecular characteristics for 
the disease-of-interest. More recently, MPE resources have matured to allow 
examination of the independent and joint influences of endogenous/lifestyle/behavioral 
factors and tissue-based molecular markers on patient prognosis and related outcomes 
(5). The underlying premise with an incidence study in an MPE paradigm is diseases 
that have certain molecular perturbations in common are more likely to share a common 
cause (or causes); similarly, for survival studies, it is postulated that 
endogenous/lifestyle/behavioral factors differentially influence prognosis according to 
molecular signatures of the disease because those factors likely interact with the 
diseased cells in the local microenvironment. To date, MPE has been largely employed 
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as a method to assess neoplastic disease heterogeneity (e.g., cancers of the 
colorectum, breast, and lung, in particular); however, MPE methods are broadly 
applicable to examining any complex disease or health condition (6). The MPE concept 
as a single, integrative field has obtained increased recognition in recent years (7-16) 
due to the increased ability to molecularly characterize tumors. 
 One of the leading opportunities in MPE research is the ability to better predict 
disease occurrence and prognosis compared to the more conventional disease entities 
without molecular classification. The evidence linking cigarette smoking and colorectal 
cancer illustrates this point. Whereas the association between smoking and lung cancer 
is robust, with relative risks (RRs) that often approach 10 when comparing long-term 
smokers to non-smokers (17), the link between smoking and colorectal cancer overall is 
much more modest, with RRs usually below 1.2 (18). Indeed, colorectal cancer was 
added to the list of smoking-associated cancers only in 2009 (19), more than five 
decades after the link between smoking and lung cancer mortality was discovered. Part 
of the obfuscation for this association is caused by tumor heterogeneity between 
individuals: colorectal cancers do not arise through a singular, homogeneous, canonical 
pathway. Instead, several major sources of genomic instability, which are not mutually 
exclusive, contribute to malignant transformation of colorectal epithelial cells: 
chromosomal instability, microsatellite instability (MSI), epigenomic instability (e.g., CpG 
island methylator phenotype, or CIMP) and somatically acquired point mutations, indels 
and copy number alterations (20). Once stratified by MSI or CIMP status, several MPE 
studies have demonstrated an approximate doubling of risk between smoking and the 
rarer MSI-high (~15% of colorectal cancers) and CIMP-high (~20% of colorectal 
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cancers) subtypes of colorectal cancer and quite consistently null associations have 
been shown for colorectal cancers not bearing those phenotypes (21-24). Beyond 
identifying previously unknown exposure-subtype disease associations and supporting 
causality, MPE studies may also identify disease subtypes that benefit from certain 
behavioral or pharmacologic interventions and discover/validate molecular markers for 
risk assessment, early detection, prognosis and prediction (6). 
 MPE studies also have several limitations that are common to observational 
research in general and to epidemiology in particular when sub-group analyses are 
performed, including the potential for bias (e.g., selection bias), limited generalizability, 
low statistical power (and the related issue of low risk estimate precision), multiple 
testing leading to potentially spurious findings, and the potential for measurement errors 
of the molecular phenotypes of interest. MPE also faces unique challenges, including 
the lack of researchers with transdisciplinary expertise in epidemiology, biostatistics, 
bioinformatics, molecular biology, pathology, and computational biology. To address 
these challenges, highlight recent successes in the field, and to identify new 
opportunities, a series of MPE meetings have been held at the Dana-Farber Cancer 
Institute in Boston, MA. The first was a closed meeting with 10 attendees held in April 
2013. The second meeting was open to the international scientific community, with 150 
attendees from 16 countries, and held in December 2014 (25). Herein, we share the 
proceedings of the Third International Molecular Pathological Epidemiology (MPE) 
Meeting, held in May 2016 and attended by 150 scientists from 17 countries. The 
session topics, speakers, and essential references are summarized in Table 1. 
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Day 1: May 12, 2016 
The meeting started with co-Chairs Drs. Shuji Ogino and Peter Campbell who 
welcomed participants and gave a brief history of the MPE meetings as well as an 
overview of the meeting’s theme (‘Concepts, Tools and Practice’) and goals. 
Updates of MPE and MPE Pooling Projects 
 The first session of the day was on ‘Updates for MPE’, with Dr. Martha Slattery 
presenting recent data from the Diet, Activity, and Lifestyle Study (DALS) (26) on 
microRNA (miRNA) profiling in normal and neoplastic tissue. MiRNAs are small, non-
protein-coding RNA molecules that regulate gene expression either by post-
transcriptionally suppressing mRNA translation or by causing mRNA degradation. In the 
study, Dr. Slattery and her colleagues profiled 1893 colorectal cancer/normal paired 
samples and 290 adenoma tissue samples on the Agilent human miRNA Microarray 
and she gave a thorough overview of some of the methodologic challenges in dealing 
with the abundance of data generated by these sorts of platforms, including the difficulty 
in selecting bioinformatics tools, interpretation of complex results, and validation of key 
findings. One of the key findings from her data was that miRNAs might influence rectal 
cancer survival outcomes more-so than colon cancer survival.  
Keeping with the theme of colorectal cancer MPE, Dr. Ulrike Peters gave a 
lecture updating the efforts of the large ‘GECCO (Genetics and Epidemiology of 
Colorectal Cancer Consortium) MPE’ project that aims to use targeted sequencing of 
about 200 genes known to be somatically mutated in 50 genomic regions for copy 
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number alterations, and bacterial genes. The content for the targeted sequencing panel 
was selected based on comprehensive analysis of large scale whole exome sequencing 
data from The Cancer Genome Atlas (TCGA) (27) and efforts in the Nurses’ Health 
Study and Health Professional Follow up study (28, 29). The GECCO consortium aims 
to test 4200 tumors and 3500 normal tissue samples in addition to harmonizing existing 
tumor molecular phenotype data (e.g., MSI, CIMP, BRAF-mutation, KRAS-mutation) 
from over 10,000 cases. Dr. Peters presented preliminary data from the first 198 cases 
and discussed the bioinformatics pipeline created for the project. In combination with 
the expansive clinical, epidemiologic and GWAS data from GECCO, which has been 
underway since 2009, the addition of tumor molecular phenotype data will create a rich 
resource for MPE discovery and validation.  
Cancer Immunology 
The second session focused on cancer immunology (chaired by Dr. Amanda 
Phipps). Dr. Harlan Robins presented a lecture on learning to read immunological 
memory using immune-sequencing (30). Part of the impetus for this work is to acquire 
the ability to detect small neoplastic clones that remain in circulation after treatment, 
which can indicate disease recurrence. He presented work to show that high clonality 
was associated with better prognosis for hematologic cancer patients. Targeted 
sequencing of T- and B-cells is likely a fruitful area for multiple tumors to investigate the 
impact of epidemiological preventive and risk factors on the immune response of the 
tumor and impact of the immune response on survival outcomes. 
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 Dr. Gordon Freeman presented a lecture describing how pathological data 
analysis may help to guide immunotherapy. He showed that approximately 30% of solid 
tumors and selected hematologic malignancies are positive for CD274 (PD-L1), an 
immune checkpoint ligand that is expressed by tumor and immune cells. The CD274-
PDCD1 (PD-1) immune checkpoint pathway is also becoming recognized as a 
promising therapeutic target in various tumor types. Pathological analysis of tumor 
immunity status including immune checkpoint has been applied to population-based 
research (31-33), which can provide new insights on variations of tumor immunity and 
influence of various exposures.  
 The final lecture in the cancer immunology session was given by Dr. Ogino who 
described how innate and adaptive immunity plays a critical role in health and disease. 
All pathologic processes involve interactions between multiple cell types, including 
immune cells, in response to environmental exposures in the tissue microenvironment. 
Hence integrated analyses of exposures, tumor molecular features, and immune 
characteristics are important to better understand disease processes such as cancers 
(34). Epidemiology has had more recent successes with, for example, germline genetics 
than with immunology, but the opportunities are now rich in this field (29, 35, 36). Dr. 
Ogino introduced how MPE methods can and should be applied to the study of immune-
based disease subtyping and provided an example of an association for high dietary 
marine omega-3 polyunsaturated fatty acids lowering risk of colorectal cancer with high-
density FOXP3+ regulatory T cells (37). 
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MPE of Cancer Disparities 
The next session was focused on the MPE of cancer disparities and chaired by 
Dr. Xuehong Zhang with one presenter, Dr. Timothy Rebbeck. Dr. Rebbeck’s lecture 
gave an overview of cancer disparities for prostate cancer mortality (38). It is well known 
that African American men have approximately double the rate of prostate cancer-
specific death compared to white men. Because prostate cancer is a disease with a 
complex, multifactorial etiology, it is clear that the disparity is explained by genomics, 
biochemistry and physiology, exposure, behavior, and social context, among other 
factors. Models of cancer etiology and disparities therefore need to consider the 
potential interaction of all of these factors to understand health and disease. Perhaps 
more importantly, it may be necessary to use these multiple etiological factors to 
redefine the disparity. That is, using race or ethnicity in defining disparities has been of 
value, but it is clear that this classification is misclassified with respect to the entities 
that may be most relevant for the development and implementation of interventions 
(e.g., cancer prevention). MPE provides a unique framework around which this 
complexity can be studied, and therefore provides a useful means to understand cancer 
disparities for diseases like prostate cancer.  
Computational Modelling and Molecular Imaging  
The final session of the morning was devoted to ‘special topics’ with two 
speakers and moderated by Dr. Rebbeck. Dr. Franziska Michor presented a lecture on 
computational modeling to analyze single-cell data obtained from biopsy and surgical 
samples of breast cancer patients (39-41). In collaboration with Dr. Kornelia Polyak from 
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the Dana-Farber Cancer Institute, Dr. Michor developed evolutionary stochastic 
modeling techniques to determine the effects of intra-tumor heterogeneity on responses 
to neoadjuvant chemotherapy. Furthermore, such spatially explicit computational 
modeling techniques can be used to identify mechanisms of tumor evolution, for 
instance whether different subtypes of breast cancer have intrinsically different 
migration rates as identified from clinical specimens. Her methods are also being 
applied to other cancer and treatment types.   
 The second ‘special topics’ lecture was on molecular imaging in future population 
screening and given by Dr. Alexei Bogdanov. Molecular imaging is the noninvasive in 
vivo investigation of cellular and molecular events involved in normal and pathologic 
processes (42). While the technology is not yet apt for population-wide screening, some 
aspects of diagnostic agent (label-free) and label-enabled molecular imaging techniques 
have evolved to play substantial roles in prospective studies. In those studies, patient 
safety, compliance, add-on time and cost are of paramount importance. In this regard, 
high-field strength clinical magnetic resonance imagining (MRI) spectroscopy has a 
proven record of providing molecular information regarding the levels of key metabolites 
in normal and cancer tissues to aid with differential diagnostic decisions. An example 
was offered with early stage prostate cancer and breast cancer detection.  
Statistical Advances in MPE 
 After a two-hour pause in podium presentations for attendees to review poster 
presentations, the afternoon sessions began with statistical advances in MPE (chaired 
by Dr. Molin Wang). Dr. Colin Begg lectured on his group’s efforts toward developing 
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sub-type specific models for absolute risk in cancer studies (43). Using examples from 
bilateral primary breast cancer data, he showed how this resource provides unique 
insights about cancer heterogeneity that cannot be discerned from traditional case-
control or cohort studies. 
 In the second presentation in this session, Dr. Tyler VanderWeele considered the 
problem of assessing mechanistic interaction when an outcome is ordinal as is the case 
with etiologic or outcome heterogeneity. Such mechanistic interaction between two 
exposures is said to be present when for some individuals a particular outcome level or 
subclass will occur if both exposures are present but will not if only one of the two 
exposures is present (44). Conditions for such mechanistic interaction for a binary 
outcome have been derived previously and do not in general coincide with the presence 
of an interaction term in a statistical model (45, 46); generally stronger empirical 
conditions are needed for the conclusion of mechanistic than simply a non-zero product 
term in a statistical model. New empirical conditions are derived for the setting when the 
outcome is ordinal. It is shown that the new conditions cannot be derived simply by 
recoding the ordinal outcomes as a series of dichotomizations. The methods are useful 
in assessing the types of interactions between exposures that may give rise to etiologic 
heterogeneity in the study of molecular pathological epidemiology. 
Computational Biology 
 The next session focused on computational biology (chaired by Dr. Reiko 
Nishihara). Dr. John Quackenbush started off the session with a lecture on patient-
specific gene regulatory networks (47). The central hypothesis to this work is that 
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unique gene regulatory processes define biological phenotypes, including those of 
populations with diseases. His group’s work over the past few years has produced 
powerful methods for inferring population-level gene regulatory networks, for comparing 
those networks between phenotypes, and for understanding biological properties of 
those phenotypes based on the features of the networks. In his lecture, he presented a 
simple extension to those models that allow one to deduce gene regulatory network 
models for each individual in a population. Further, he showed that these patient-
specific networks are predictive of important biological endpoints, and in many cases 
are more predictive than widely-used biomarkers. More importantly, these patient-
specific networks might provide a path to a more directed and individualized approach 
to treatment.   
In the second lecture in this session, Dr. Rafael Irizarry presented data on high 
dimensional epigenomic analysis wherein he described some of the statistical and 
biological challenges related to detecting differentially methylated genomic regions (48). 
He described the important role of modern statistical techniques in finding regions of the 
genome that are consistently different between diseased and normal groups and some 
new challenges that are specifically related to next-generation sequencing data. He also 
described the importance of considering batch effects which often exist in high-
throughput data.  
Dr. Curtis Huttenhower gave a lecture on high-precision functional profiling of 
microbial communities and the human microbiome. Human gut microbial dysbioses 
have been associated with diseases ranging from autism to cancer, but the causative 
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molecular or ecological mechanisms are unclear (49). He presented end-to-end 
methodologies for functional surveys of the microbiome in human population studies, 
beginning with scalable sample collection and including computational tools and 
downstream statistical analyses. These have, to date, identified potentially causal 
microbial mechanisms in inflammatory bowel disease and type 1 diabetes mellitus, and 
he discussed strategies for future applications and open questions in colorectal cancer, 
nutrition, and the microbiome more broadly in public health. 
Proffered Abstracts: Part 1 
The last session of the first day, chaired by Dr. Elizabeth Poole, was devoted to 
proffered papers from submitted abstracts.  
Ms. Emily Zabor reviewed statistical methods for evaluating etiologic 
heterogeneity. One focus of MPE is the classification of diseases into subtypes based 
on molecular and pathological characteristics, and subsequent application of 
epidemiologic methods to study the resulting subtypes. A particular interest of 
epidemiologists is the etiologic heterogeneity of the sub-types, i.e. differences across 
subtypes with respect to the influence of risk factors. She reviewed a variety of methods 
that have been proposed to study etiologic heterogeneity, including the standard 
polytomous regression approach (50), a method that incorporates subtype discovery 
with a scalar measure of the degree of heterogeneity (51), several two-stage regression 
approaches that are applicable both to cohort and case-control studies (52, 53), a 
single-stage regression approach that introduces the concept of an adjusted hazard 
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ratio (54), and a method that allows for non-mutually exclusive subtype membership 
(55). 
Dr. Daniel Nevo lectured on his work in dealing with missing subtypes using 
auxiliary case covariates. A competing risks proportional hazard model is often used in 
the analysis of time-to-disease data to assess risk factor associations on different 
disease subtypes (56, 57). Cases with missing subtypes are often ignored, and even 
when these cases are included, the analysis is typically based on a missing-at-random 
assumption. For example, colorectal tumors that harbor molecular perturbations that are 
linked to poorer prognosis may be less likely to be accrued, leading to a potential bias of 
the observed risk factor and subtype associations. He described a method to conduct 
valid analyses when additional auxiliary variables are measured for cases. The method 
exploits the fact that distribution of the auxiliary case covariates differs according to the 
molecular subtype. He illustrated the use of the new method in the analysis of colorectal 
cancer data from the Nurses' Health Study. The auxiliary covariate was tumor location, 
which is commonly accrued for most cases. The method used the fact that a proximal 
tumor location is more likely to occur among MSI-high subtype tumors compared to 
microsatellite stable subtypes to correct potential bias. 
Dr. Yujing Jan Heng gave a lecture on molecular analyses of histopathologic 
features in breast cancer. Her group collected histopathologic annotation of invasive 
breast cancer cases in the TCGA (58) and integrated TCGA’s molecular data with 
breast cancer histopathologic annotations to elucidate the molecular basis of common 
morphologic features. Her study found that certain molecular features in breast cancer 
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were associated with the PAM50 Basal-like subtype. They also used omics-based 
multivariate models to assess the association of morphologic signatures with survival in 
ESR1 (ER-alpha)-positive and ESR1 (ER-alpha)-negative breast cancer using six 
independent datasets. They identified that a transcriptomic signature of poorly 
differentiated epithelial tubule formation adds prognostic information in ESR1-positive 
beyond pathologic assessment of clinical grade.  
Day 2: May 13, 2016 
Proffered Abstracts: Part 2 
 The second day of the meeting began with another session for proffered 
abstracts as well as the announcement of trainee awards at the student/post-doctoral 
and early career levels (chaired by Dr. N. Sertac Kip). 
 Dr. Daniel Xia lectured on the role of computational pathology to identify stromal 
inflammation as a prognostic biomarker in squamous cell carcinoma (SCC) of the lung.  
His group did high-throughput computational digital image analyses on tissue 
microarray (TMA) samples of tumors from lung SCC cases, with the goal of identifying 
epithelial and stromal histologic features associated with survival and they identified a 
stromal inflammation (SI) score was prognostic for patient survival outcomes. The SI 
histologic score was positively correlated with the expression of genes involved in the 
adaptive immune response in TCGA data. 
Dr. Peter Rogan gave a lecture on cisplatin response in recurrent bladder cancer 
with biochemically-inspired machine learning. The ability to predict response to 
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chemotherapy could help with drug selection and dosing, possibly reduce toxicity, and 
improve outcomes. Using a machine learning approach (59), models were developed 
for the prediction of cisplatin chemotherapy response in bladder cancer patients. 
Thegene expression signatures were validated in TCGA patients. Machine learning 
experiments identified gene sets that were enriched for genes belonging to DNA repair, 
anti-oxidative response, and metal binding pathways.  
Dr. Helen Coleman presented work on low-dose aspirin, PTGS2 expression and 
survival in colon cancer patients using data from Northern Ireland. The association 
between high-dose aspirin use and improved survival after colorectal cancer diagnosis 
may be more pronounced for patients who have tumors with high prostaglandin 
endoperoxide synthase 2 (PTGS2, cyclooxygenase-2) expression (60). The interaction 
between PTGS2 and low-dose aspirin is less clear (61, 62).  QuPath image analysis 
software assessed immunohistochemical expression of PTGS2 in TMAs. Clinical follow-
up data were obtained through the Northern Ireland Cancer Registry. Compared to 
nonusers, low-dose aspirin users had lowered risks of cancer-specific mortality and all-
cause mortality. Low dose aspirin use was associated with improved overall survival for 
tumors that overexpressed PTGS2 but not for tumors with weaker PTGS2 expression.  
Dr. Yin Cao gave a lecture on aspirin use and risk of colorectal cancer according 
to tumor immune reaction. She hypothesized that aspirin use might be associated with 
lower risk of colorectal cancers that demonstrated less immune response because of 
aspirin’s immune-enhancing effects. Aspirin use data were collected in the Nurses' 
Health Study and Health Professionals Follow-up Study (63). The inverse association of 
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regular aspirin use with colorectal cancer risk differed by the degree of tumor infiltrating 
lymphocytes (TILs). Compared with non-regular use, regular aspirin-use was associated 
with lower risk of tumor with low-level TILs, and the strength of the association was 
dose- and duration-dependent. In contrast, aspirin use was not associated with risk of 
tumors with intermediate-level or high-level TILs. These results suggest a potential role 
of host immunity in mediating the chemopreventive effect of aspirin. 
Open discussion Part 1: illustration of MPE studies from beginning to end 
 In the first of two open discussion sessions, Dr. Campbell illustrated how tissue 
collection can be initiated from within an existing prospective cohort study and how 
existing MPE resources can be leveraged to build an early career in MPE. In the first 
part of his lecture, the basic methods and challenges faced in creating a tissue 
repository from an ongoing prospective cohort study, the Cancer Prevention Study-II, 
were outlined, including the timeline, methodology and resources required for such 
endeavors (64). Study participants with and without tissue materials were compared on 
a series of epidemiologic and clinical factors and few differences were found. One of the 
main challenges in collecting tissue materials in this context was that surgical tissue 
materials are usually destroyed by hospitals 10-years after the patient’s diagnosis. In 
the second part of the lecture, he reviewed work that primarily focused on real-world 
challenges involved with complex MPE studies, notably the vast bioinformatics 
resources, from the Colon Cancer Family Registry (65-68) as an example toward 
building an early career in MPE from an existing resource.  
Open Discussion Part 2: general issues relevant to MPE  
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 In the second open discussion session, Drs. Heng, Kip and Mingyang Song 
discussed the paucity of interdisciplinary education and training opportunities in MPE 
and how they overcame these obstacles in their own careers. Drs. Begg and Wang led 
an open discussion on study design and statistical challenges for MPE with lots of 
feedback from audience members on their own experiences. Drs. Andrew Beck, Kip 
and Zhi Rong Qian discussed opportunities and challenges in the disconnect between 
pathology (focused on the singular patient) and epidemiology (focused on populations). 
Drs. Peters and Stephanie Smith-Warner led a discussion on consortia building, based 
on their experiences with GECCO and various NCI-Cohort Consortium projects. Dr. 
Rebbeck led the group in a discussion on cancer health disparities and how MPE may 
address some of these issues. The session came to a close with Drs. Beck, Bogdanov 
and Poole leading a discussion on emerging technologies and new areas of 
investigation. 
Conclusions 
 The Third International MPE Meeting successfully assembled 150 trainees and 
experts working in complementary fields of this rather new scientific discipline. As the 
heterogeneity of pathogenic processes in human complex diseases becomes better 
appreciated and understood, the MPE paradigm should become more ubiquitous in the 
future for many areas of clinical medicine and population health sciences. We look 
forward to again sharing our experiences, successes and challenges at the Fourth 
International MPE Meeting, which is planned to be held in the spring of 2018.    
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